The company now has an insider ownership of 0.3 Percent and Institutional ownership of 87.2 Percent. The medical equipment provider reported $0.34 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.34.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. When we divide the last trade volume by the 3-month average volume, we found out a relative volume of 1.13. About 1.64M shares traded.
Analyst research firms are expressing bullish stance on Boston Scientific Corporation (NYSE:BSX)'s near-term growth potential. It has outperformed by 2.42% the S&P500. The company operates in the Real Estate sector with a market capitalization of 6.71 Million. Incline Global Management Llc bought 208,065 shares as the company's stock rose 3.82% with the market.
Price Michael F increased S&W Seed Company (NASDAQ:SANW) stake by 1.31M shares to 4.51M valued at $14.20M in 2017Q3. The stock increased 0.30% or $0.05 during the last trading session, reaching $16.85. About 101,186 shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since February 12, 2017 and is uptrending.
Boston Scientific Corporation was covered by a number of analysts recently, 13 rated the stock as Buy, 5 rated Hold, 0 rated sell and 0 gave an Underperform. Boston Scientific has a 1-year low of $23.29 and a 1-year high of $29.93. The stock has an average rating of "Buy" and a consensus price target of $31.00. Finally, Royal Bank of Canada reaffirmed a "buy" rating and set a $31.00 target price on shares of Boston Scientific in a report on Tuesday, November 7th. Many experts agree that the truth about a stock is best reflected in the way it moves on the chart.
Following previous ticker characteristics, Boston Scientific Corporation (NYSE:BSX) also run on active notice, stock price surged 2.86% after traded at $25.92 in most recent trading session. The firm has "Corporate" rating given on Thursday, October 29 by FinnCap. RBC Capital Markets maintained Boston Scientific Corporation (NYSE:BSX) rating on Thursday, February 1. Needham has "Buy" rating and $29 target. It also increased its holding in Cedar Fair LP (NYSE:FUN) by 176,100 shares in the quarter, for a total of 283,956 shares, and has risen its stake in Nustar Energy Lp (NYSE:NS). Price Michael F sold 215,800 shares as Boston Scientific Corp. Boston Scientific now has $35.71B valuation. Overall, 2.79 Million shares exchanged hands versus its average volume of $2.57 Million. Bose Supratim sold 347,137 shares worth $10.11M.
Investors sentiment increased to 1.04 in Q3 2017. It is positive, as 33 investors sold BSX shares while 166 reduced holdings. Johnson Financial Group stated it has 0% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Next Finance Group has 167 shares for 0% of their portfolio. Dnb Asset Mngmt As, a Norway-based fund reported 133,650 shares. Whittier Trust Of Nevada invested in 0% or 1,117 shares. Lmr Prtn Limited Liability Partnership owns 19,581 shares. Ing Groep Nv holds 0.03% or 48,414 shares in its portfolio.
Boston Scientific (NYSE:BSX) last announced its earnings results on Thursday, February 1st. Chevy Chase Tru owns 1.20M shares or 0.16% of their United States portfolio. Corporate insiders own 0.74% of the company's stock. Goelzer Invest Inc holds 0.26% or 75,021 shares in its portfolio. The amount of a company's shares outstanding is not fixed, but may vary extensively over time.
VEREIT, Inc. (NYSE:VER) touched its 1-Year High price of $9.12 on 02/27/17 and its 1-Year Low price of $6.68 on 02/09/18. S&Co has invested 0.7% in Boston Scientific Corporation (NYSE:BSX). Its down 0.47, from 1.93 in 2017Q2. It dived, as 15 investors sold EPZM shares while 22 reduced holdings. 59 funds opened positions while 158 raised stakes. Marshall Wace Limited Liability Partnership owns 80,956 shares. Legal And General Public Limited Co holds 11,139 shares. Voya Invest Lc reported 605,089 shares.
Short Ratio of stock is 1.54. Bluecrest Cap owns 17,813 shares. Strs Ohio holds 0% or 32,291 shares in its portfolio. Citadel Advsr Ltd Co holds 437,849 shares. Rhumbline Advisers reported 0% in Epizyme, Inc.
What do the analysts think? (BSX) stake by 43.16% reported in 2017Q3 SEC filing. As per Monday, July 24, the company rating was maintained by Oppenheimer. The firm has "Buy" rating given on Tuesday, January 9 by Leerink Swann. As per Wednesday, October 28, the company rating was maintained by Needham. The rating was maintained by Oppenheimer with "Buy" on Wednesday, June 21. If market is up, the stock should outperform by positive momentum and if the market heads lower, the stock should go down by same tendency. The firm earned "Buy" rating on Tuesday, May 10 by Mizuho. As per Friday, September 1, the company rating was maintained by RBC Capital Markets. MOTT DAVID M also bought $3.05M worth of Epizyme, Inc. 72,264 shares were sold by Ros Matthew, worth $1.20 million.